Preventive and Risk Reduction Strategies for Women at High Risk of Developing Breast Cancer: a Review

  • Published : 2016.04.11


Breast cancer is the most commonly diagnosed invasive cancer among women. Many factors, both genetic and non-genetic, determine a woman's risk of developing breast cancer and several breast cancer risk prediction models have been proposed. It is vitally important to risk stratify patients as there are now effective preventive strategies available. All women need to be counseled regarding healthy lifestyle recommendations to decrease breast cancer risk. As such, management of these women requires healthcare professionals to be familiar with additional risk factors so that timely recommendations can be made on surveillance/risk-reducing strategies. Breast cancer risk reduction strategies can be better understood by encouraging the women at risk to participate in clinical trials to test new strategies for decreasing the risk. This article reviews the advances in the identification of women at high risk of developing breast cancer and also reviews the strategies available for breast cancer prevention.


  1. Antoniou AC, Cunningham AP, Peto J, et al (2008). The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer, 98, 1457-66.
  2. Bagnardi V, Rota M, Botteri E, et al (2013). Light alcohol drinking and cancer: a meta-analysis. Ann Oncol, 24, 301-8.
  3. Banerji S, Cibulskis K, Rangel-Escareno C, et al (2012). Sequence analysis of mutations and translocations across breast cancer subtypes. Nature, 486, 405-9.
  4. Baum M, Budzar AU, Cuzick J, et al (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 359, 2131-9.
  5. Bertone-Johnson ER, Chen WY, Holick MF, et al (2005). Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev, 14, 1991-7.
  6. Berx G, Staes K, van Hengel J, et al (1995). Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics, 26, 281-9.
  7. Boyd NF, Guo H, Martin LJ, et al (2007). Mammographic density and the risk and detection of breast cancer. N Engl J Med, 356, 227-36.
  8. Bubien V, Bonnet F, Brouste V, et al (2013). High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet, 50, 255-63.
  9. Cauley JA, Norton L, Lippman ME, et al (2001). Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat, 65, 125-34.
  10. Chiu SY, Duffy S, Yen AM, et al (2010). Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening. Cancer Epidemiol Biomarkers Prev, 19, 1219-28.
  11. Chlebowski RT, Anderson GL, Gass M, et al (2010). Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA, 304, 1684-92.
  12. Claus EB, Risch N, Thompson WD (1994). Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer, 73, 643-51.<643::AID-CNCR2820730323>3.0.CO;2-5
  13. Collaborative Group on Hormonal Factors in Breast Cancer (2002). Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet, 360, 187-95.
  14. Cuzick J, Sestak I, Bonanni B, et al (2013). Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet, 381, 1827-34.
  15. Cuzick J, Sestak I, Cawthorn S, et al (2015). Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol, 16, 67-75.
  16. Cuzick J, Sestak I, Forbes JF, et al (2014). Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet, 383, 1041-8.
  17. De Felice F, Marchetti C, Musella A, et al (2015). Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Ann Surg Oncol, 22, 2876-80.
  18. DeSantis CE, Fedewa SA, Goding Sauer A, et al (2015). Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin.
  19. Donnelly LS, Evans DG, Wiseman J, et al (2014). Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer, 110, 1681-7.
  20. Eliassen AH, Colditz GA, Rosner B, et al (2006). Adult weight change and risk of postmenopausal breast cancer. JAMA, 296, 193-201.
  21. Ellis MJ, Ding L, Shen D, et al (2012). Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature, 486, 353-60.
  22. Emaus MJ, van Gils CH, Bakker MF, et al (2014). Weight change in middle adulthood and breast cancer risk in the EPIC-PANACEA study. Int J Cancer, 135, 2887-99.
  23. Fisher B, Costantino JP, Wickerham DL, et al (2005). Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst, 97, 1652-62.
  24. Fisher B, Costantino JP, Wickerham DL, et al (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst, 90, 1371-88.
  25. Gail MH, Costantino JP (2001). Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst, 93, 334-5.
  26. Ghosh K, Vachon CM, Pankratz VS, et al (2010). Independent association of lobular involution and mammographic breast density with breast cancer risk. J Natl Cancer Inst, 102, 1716-23.
  27. Goss PE, Ingle JN, Ales-Martinez JE, et al (2011). Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med, 364, 2381-91.
  28. Grady D, Cauley JA, Geiger MJ, et al (2008). Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst, 100, 854-61.
  29. Hamm RM, Lawler F, Scheid D (1999). Prophylactic mastectomy in women with a high risk of breast cancer. N Engl J Med, 340, 1837-8.
  30. Hartmann LC, Radisky DC, Frost MH, et al (2014). Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res, 7, 211-7.
  31. Hartmann LC, Sellers TA, Schaid DJ, et al (2001). Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst, 93, 1633-7.
  32. Howard RA, Leitzmann MF, Linet MS, et al (2009). Physical activity and breast cancer risk among pre- and postmenopausal women in the U.S. Radiologic Technologists cohort. Cancer Causes Control, 20, 323-33.
  33. King MC, Marks JH, Mandell JB (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302, 643-6.
  34. Kotsopoulos J, Olopado OI, Ghadirian P, et al (2005). Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res, 7, 833-43.
  35. Kuerer HM, Buzdar AU, Mittendorf EA, et al (2011). Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer, 117, 39-47.
  36. Kurian AW, Sigal BM, Plevritis SK (2010). Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol, 28, 222-31.
  37. LaCroix AZ, Chlebowski RT, Manson JE, et al (2011). Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA, 305, 1305-14.
  38. LaCroix AZ, Powles T, Osborne CK, et al (2010). Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst, 102, 1706-15.
  39. Lazzeroni M, Serrano D, Dunn BK, et al (2012). Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. Breast Cancer Res, 14, 214.
  40. Lord SJ, Lei W, Craft P, et al (2007). A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer, 43, 1905-17.
  41. Mahoney MC, Bevers T, Linos E, et al (2008). Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin, 58, 347-71.
  42. Maresso KC, Tsai KY, Brown PH, et al (2015). Molecular cancer prevention: Current status and future directions. CA Cancer J Clin, 65, 345-83.
  43. Maunsell E, Goss PE, Chlebowski RT, et al (2014). Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol, 32, 1427-36.
  44. McTiernan A, Martin CF, Peck JD, et al (2005). Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial. J Natl Cancer Inst, 97, 1366-76.
  45. Meijers-Heijboer H, van Geel B, van Putten WL, et al (2001). Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med, 345, 159-64.
  46. Michels KB, Willett WC (2009). The Women's Health Initiative Randomized Controlled Dietary Modification Trial: a post-mortem. Breast Cancer Res Treat, 114, 1-6.
  47. Nkondjock A, Robidoux A, Paredes Y, et al (2006). Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat, 98, 285-94.
  48. Pankratz VS, Hartmann LC, Degnim AC, et al (2008). Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol, 26, 5374-9.
  49. Parmigiani G, Berry D, Aguilar O (1998). Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet, 62, 145-58.
  50. Pharoah PD, Day NE, Duffy S, et al (1997). Family history and the risk of breast cancer: a systematic review and metaanalysis. Int J Cancer, 71, 800-9.<800::AID-IJC18>3.0.CO;2-B
  51. Powles TJ, Diem SJ, Fabian CJ, et al (2012). Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat, 134, 299-306.
  52. Quante AS, Whittemore AS, Shriver T, et al (2015). Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk. J Natl Cancer Inst, 107.
  53. Rebbeck TR, Friebel T, Lynch HT, et al (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol, 22, 1055-62.
  54. Rebbeck TR, Kauff ND, Domchek SM (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst, 101, 80-7.
  55. Saslow D, Boetes C, Burke W, et al (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin, 57, 75-89.
  56. Shah SP, Roth A, Goya R, et al (2012). The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 486, 395-9.
  57. Stephens PJ, Tarpey PS, Davies H, et al (2012). The landscape of cancer genes and mutational processes in breast cancer. Nature, 486, 400-4.
  58. Tehard B, Friedenreich CM, Oppert JM, et al (2006). Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev, 15, 57-64.
  59. Tice JA, Miglioretti DL, Li CS, et al (2015). Breast density and benign breast disease: risk assessment to identify women at high risk of breast cancer. J Clin Oncol, 33, 3137-43.
  60. Travis LB, Hill D, Dores GM, et al (2005). Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst, 97, 1428-37.
  61. Tyrer J, Duffy SW, Cuzick J (2004). A breast cancer prediction model incorporating familial and personal risk factors. Stat Med, 23, 1111-30.
  62. van Lier MG, Wagner A, Mathus-Vliegen EM, et al (2010). High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol, 105, 1258-65.
  63. Visvanathan K, Hurley P, Bantug E, et al (2013). Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 31, 2942-62.
  64. Vogel VG, Costantino JP, Wickerham DL, et al (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 295, 2727-41.
  65. Vogel VG, Costantino JP, Wickerham DL, et al (2010). Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res, 3, 696-706.
  66. Vogel VG, Qu Y, Wong M, et al (2009). Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration. Clin Breast Cancer, 9, 45-50.
  67. Wong CS, Lim GH, Gao F, et al (2011). Mammographic density and its interaction with other breast cancer risk factors in an Asian population. Br J Cancer, 104, 871-4.
  68. Yang XR, Chang-Claude J, Goode EL, et al (2011). Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst, 103, 250-63.
  69. Zhang Y, Zhang M, Yuan X, et al (2015). Association between ESR1 PvuII, XbaI, and P325P polymorphisms and breast cancer susceptibility: a meta-analysis. Med Sci Monit, 21, 2986-96.

Cited by

  1. The role of health policy in the burden of breast cancer in Brazil vol.17, pp.1, 2017,